THALES
Thales today announced the launch of its CipherTrust Cloud Key Manager integration with the AWS External Key Store, a feature of the AWS Key Management Service announced at AWS re:Invent 2022. Following an increased call for enhanced sovereign controls amid growing regulatory requirements, the integration enables organisations to retain control of their encryption keys when migrating their sensitive data to the AWS cloud.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130005542/en/
©Thales
Developed with Thales since its inception, the AWS External Key Store combined with CipherTrust Cloud Key Manager offers organisations looking to move critical workloads to the cloud a way to maintain sovereign control of sensitive data throughout their digital transformation journey.
“We’ve had a strong technical collaboration with Thales on the development of the AWS External Key Store specification from the very beginning, in part due to their long history of expertise developing hardware security modules and key management services,” said Ken Beer, General Manager, Key Management Service at AWS. “The cloud has become a critical point of operation across businesses, and our combined expertise provides a way of helping organisations address specific needs and know they’re getting industry-best security controls in the process.”
According to the Thales 2022 Cloud Security Study, encryption is the number one choice to protect data in the cloud. However, only about one-third (29%) of respondents report total control of their keys to encrypted data in the cloud. User-controlled encryption and key management in hybrid IT are essential safeguards to enforce digital sovereignty in a modern data-driven world governed by privacy compliance mandates, regulated sectors, or general IT security recommendations such as the Shared Responsibility Model and the NIS2 Directive.
CipherTrust Cloud Key Manager ensures AWS External Key Store customers can satisfy these urgent regulatory requirements by leveraging strong encryption and data security methods that allow organisations to manage their data separately from the cloud service provider. Such a safeguard, also known as Hold Your Own Key (HYOK), enables organisations to maintain key ownership separate from the cloud data store.
“Varying data protection regulations across countries have presented a challenge for global organisations migrating to the cloud,” said Heleen Herselman, VP AWS Powerhouse at T-Systems Cloud Service. “The CipherTrust Cloud Key Manager simplifies this challenge and ensures we remain compliant while taking advantage of all the benefits of leveraging cloud services. The ability to lean on Thales’ solution has become especially important, as we, and other organisations, increasingly rely on multi-cloud environments.”
CipherTrust Cloud Key Manager is an industry-leading multi-cloud encryption key life cycle management solution that supports all major public cloud service providers. With a marked increase in multi-cloud adoption, this solution allows users to centralise key management across all clouds.
“This is the first integration on the market to solve a major pain point for AWS cloud customers: how can they utilise protected data in the AWS cloud while retaining encryption keys outside the cloud.” said Todd Moore, VP, Encryption Products at Thales. “As an industry leader in key management solutions, we are proud to offer an encryption solution that provides the ability to maintain external control of keys and cryptographic operations using those keys. CipherTrust Cloud Key Manager is at the forefront of advanced digital sovereignty. We’ll continue to introduce cutting-edge security and compliance features that support organisations in their digital transformation journeys.”
The Thales CipherTrust Cloud Key Manager integration for AWS External Key Store is available today. For more information, visit our landing page.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.
PLEASE VISIT
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221130005542/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
